STE Stock Recent News
STE LATEST HEADLINES
Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, IRELAND, Jan. 28, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on March 21, 2025, to shareholders of record at the close of business on February 20, 2025.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025
DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9:00 a.m. ET on February 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
DUBLIN, IRELAND, Jan. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that a jury trial that had been ongoing since December 4, 2024, against Isomedix Operations, Inc. (“Isomedix”), a subsidiary of the Company, ended in a mistrial on January 17, 2025.